AzurRx BioPharma, Inc.
Company Snapshot: AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections.
- Jun 29 2018 AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency
- May 30 2018 AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer
- May 1 2018 AzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common Stock
- Apr 30 2018 AzurRx BioPharma Announces Proposed Public Offering of Common Stock